

Renata Talar-Wojnarowska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9042197/publications.pdf>

Version: 2024-02-01

61
papers

1,465
citations

393982

19
h-index

344852

36
g-index

62
all docs

62
docs citations

62
times ranked

3083
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurological Manifestations and Psychiatric Disorders in the Course of Inflammatory Bowel Diseases. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2022, 31, 107-118.	0.5	1
2	Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. <i>Journal of Medical Genetics</i> , 2021, 58, 369-377.	1.5	31
3	Brain-derived neurotrophic factor is elevated in the blood serum of Crohn's disease patients, but is not influenced by anti-TNF treatment – A pilot study. <i>Neurogastroenterology and Motility</i> , 2021, 33, e13978.	1.6	19
4	Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110364.	1.4	5
5	Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. <i>Scientific Reports</i> , 2021, 11, 7570.	1.6	2
6	Intestinal amyloidosis: Clinical manifestations and diagnostic challenge. <i>Advances in Clinical and Experimental Medicine</i> , 2021, 30, 563-570.	0.6	13
7	Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. <i>Carcinogenesis</i> , 2021, 42, 1037-1045.	1.3	14
8	Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. <i>Frontiers in Genetics</i> , 2021, 12, 693933.	1.1	10
9	Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2342-2345.	1.1	4
10	Leukocytapheresis in patients with inflammatory bowel diseases. <i>Przegląd Gastroenterologiczny</i> , 2021, 16, 99-105.	0.3	0
11	Serum Levels of Chemerin in Patients with Inflammatory Bowel Disease as an Indicator of Anti-TNF Treatment Efficacy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4615.	1.0	3
12	Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 5660.	1.0	16
13	Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. <i>Frontiers in Oncology</i> , 2021, 11, 771312.	1.3	8
14	The Association between Temperament, Chronotype, Depressive Symptoms, and Disease Activity among Patients with Inflammatory Bowel Disease – A Cross-Sectional Pilot Study. <i>Life</i> , 2021, 11, 1347.	1.1	1
15	Determinants of Sleep Quality in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 2921.	1.0	30
16	Procoagulant Disorders in Patients with Newly Diagnosed Pancreatic Adenocarcinoma. <i>Medicina (Lithuania)</i> , 2020, 56, 677.	0.8	4
17	Efficiency and safety of one-year anti-TNF treatment in Crohn's disease: a Polish single-centre experience. <i>Przegląd Gastroenterologiczny</i> , 2020, 15, 156-160.	0.3	7
18	Genome-wide association study identifies an early onset pancreatic cancer risk locus. <i>International Journal of Cancer</i> , 2020, 147, 2065-2074.	2.3	20

#	ARTICLE	IF	CITATIONS
19	A simple index to predict the efficiency of adalimumab treatment in Crohn's disease with a limited duration of therapy. Polish Archives of Internal Medicine, 2020, 130, 910-912.	0.3	7
20	Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Carcinogenesis, 2019, 40, 544-550.	1.3	8
21	Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. Przegląd Gastroenterologiczny, 2019, 14, 1-18.	0.3	64
22	The prevalence, characteristics, and determinants of anaemia in newly diagnosed patients with inflammatory bowel disease. Przegląd Gastroenterologiczny, 2019, 14, 39-47.	0.3	9
23	Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. International Journal of Cancer, 2019, 144, 1275-1283.	2.3	36
24	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	5.8	188
25	Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Carcinogenesis, 2018, 39, 360-367.	1.3	16
26	Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. International Journal of Cancer, 2018, 142, 290-296.	2.3	14
27	Diagnostic and therapeutic recommendations for chronic pancreatitis. Recommendations of the Working Group of the Polish Society of Gastroenterology and the Polish Pancreas Club. Przegląd Gastroenterologiczny, 2018, 13, 167-181.	0.3	7
28	SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Scientific Reports, 2017, 7, 43812.	1.6	15
29	Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1349-1351.	1.1	5
30	Possible under-treatment of women in Poland with Crohn's disease: a subgroup analysis from a prospective multicenter study of the use of anti-TNFs. Polish Archives of Internal Medicine, 2017, 127, 674-680.	0.3	3
31	Management of acute pancreatitis (AP) – Polish Pancreatic Club recommendations. Przegląd Gastroenterologiczny, 2016, 2, 65-72.	0.3	10
32	Analysis of XRCC2 and XRCC3 gene polymorphisms in pancreatic cancer. Biomedical Reports, 2016, 4, 236-240.	0.9	9
33	Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. Scientific Reports, 2016, 6, 39565.	1.6	15
34	Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Carcinogenesis, 2016, 37, 957-964.	1.3	14
35	Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Oncotarget, 2016, 7, 57011-57020.	0.8	41
36	Utility of different serum fibrosis markers in diagnosing patients with chronic pancreatitis and pancreatic adenocarcinoma. World Journal of Gastrointestinal Oncology, 2016, 8, 635.	0.8	5

#	ARTICLE	IF	CITATIONS
37	<sc><i>TERT</i></sc> gene harbors multiple variants associated with pancreatic cancer susceptibility. <i>International Journal of Cancer</i> , 2015, 137, 2175-2183.	2.3	57
38	Utility of serum IgG, IgG4 and carbonic anhydrase II antibodies in distinguishing autoimmune pancreatitis from pancreatic cancer and chronic pancreatitis. <i>Advances in Medical Sciences</i> , 2014, 59, 288-292.	0.9	22
39	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. <i>Nature Genetics</i> , 2014, 46, 994-1000.	9.4	294
40	Role of adipocytokines and its correlation with endocrine pancreatic function in patients with pancreatic cancer. <i>Pancreatology</i> , 2013, 13, 409-414.	0.5	26
41	Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. <i>Digestive and Liver Disease</i> , 2013, 45, 95-99.	0.4	45
42	Lack of Replication of Seven Pancreatic Cancer Susceptibility Loci Identified in Two Asian Populations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 320-323.	1.1	20
43	Pancreatic cyst fluid analysis for differential diagnosis between benign and malignant lesions. <i>Oncology Letters</i> , 2013, 5, 613-616.	0.8	28
44	ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium. <i>Oncology Reports</i> , 2013, 29, 1637-1644.	1.2	55
45	Insulin, insulin-like growth factor 1 and insulin-like growth factor binding protein 3 serum concentrations in patients with adenomatous colon polyps. <i>Przegląd Gastroenterologiczny</i> , 2013, 5, 308-314.	0.3	4
46	A comparative analysis of K-ras mutation and carcinoembryonic antigen in pancreatic cyst fluid. <i>Pancreatology</i> , 2012, 12, 417-420.	0.5	22
47	Evaluation of pH-impedance testing in diagnosis of patients with suspected extra-oesophageal manifestations of gastroesophageal reflux disease. <i>Przegląd Gastroenterologiczny</i> , 2012, 6, 386-396.	0.3	2
48	Clinical Value of Serum Neopterin, Tissue Polypeptide-Specific Antigen and CA19-9 Levels in Differential Diagnosis between Pancreatic Cancer and Chronic Pancreatitis. <i>Pancreatology</i> , 2011, 10, 689-694.	0.5	21
49	Surgical treatment of pancreatic cancer – randomized controlled trials. <i>Przegląd Gastroenterologiczny</i> , 2011, 3, 133-138.	0.3	3
50	Efficacy and safety of biological treatment in Crohn’s disease: our experience. <i>Przegląd Gastroenterologiczny</i> , 2011, 5, 304-309.	0.3	0
51	Guidelines for diagnosis and treatment of chronic pancreatitis. Recommendations of Working Group of the Polish National Consultant in gastroenterology and Polish Pancreatic Club. <i>Przegląd Gastroenterologiczny</i> , 2011, 6, 339-352.	0.3	6
52	The Prevalence of Cationic Trypsinogen (PRSS1) and Serine Protease Inhibitor, Kazal Type 1 (SPINK1) Gene Mutations in Polish Patients with Alcoholic and Idiopathic Chronic Pancreatitis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 894-901.	1.1	32
53	Role of cyclooxygenase-2 gene polymorphisms in pancreatic carcinogenesis. <i>World Journal of Gastroenterology</i> , 2011, 17, 4113.	1.4	15
54	Prevalence of the N34S mutation of SPINK1 (serine protease inhibitor, Kazal type 1) in patients with chronic pancreatitis and pancreatic cancer. <i>Przegląd Gastroenterologiczny</i> , 2010, 4, 214-221.	0.3	1

#	ARTICLE	IF	CITATIONS
55	Outcome of pseudocysts complicating chronic pancreatitis. Hepato-Gastroenterology, 2010, 57, 631-4.	0.5	1
56	Clinical Significance of Interleukin-6 (Il-6) Gene Polymorphism and Il-6 Serum Level in Pancreatic Adenocarcinoma and Chronic Pancreatitis. Digestive Diseases and Sciences, 2009, 54, 683-689.	1.1	89
57	Assessment of frequency and safety of endoscopic retrograde cholangiopancreatography in patients over 80 years of age. , 2009, 119, 136-40.		9
58	Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Medical Science Monitor, 2006, 12, RA186-93.	0.5	34
59	Comparative evaluation of p53 mutation in pancreatic adenocarcinoma and chronic pancreatitis. Hepato-Gastroenterology, 2006, 53, 608-12.	0.5	4
60	Clinical Significance of K-ras and c-erbB-2 Mutations in Pancreatic Adenocarcinoma and Chronic Pancreatitis. International Journal of Gastrointestinal Cancer, 2005, 35, 033-042.	0.4	18
61	Molecular Basis of Pancreatic Cancer--Selected Issues. Gastrointestinal Oncology, 2002, 4, 147-152.	0.1	1